Search

Your search keyword '"Gicobi, Joanina K."' showing total 28 results
Start Over Author "Gicobi, Joanina K."
28 results on '"Gicobi, Joanina K."'

2. Supplementary Figure from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

Author

Wen, Ti, primary, Barham, Whitney, primary, Li, Ying, primary, Zhang, Henan, primary, Gicobi, Joanina K., primary, Hirdler, Jacob B., primary, Liu, Xin, primary, Ham, Hyoungjun, primary, Peterson Martinez, Kodi E., primary, Lucien, Fabrice, primary, Lavoie, Roxane R., primary, Li, Hu, primary, Correia, Cristina, primary, Monie, Dileep D., primary, An, Zesheng, primary, Harrington, Susan M., primary, Wu, Xiaosheng, primary, Guo, Ruifeng, primary, Dronca, Roxana S., primary, Mansfield, Aaron S., primary, Yan, Yiyi, primary, Markovic, Svetomir N., primary, Park, Sean S., primary, Sun, Jie, primary, Qin, Hong, primary, Liu, Minetta C., primary, Vasmatzis, George, primary, Billadeau, Daniel D., primary, and Dong, Haidong, primary

Published
2024
Full Text
View/download PDF

3. Supplementary Data from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

Author

Wen, Ti, primary, Barham, Whitney, primary, Li, Ying, primary, Zhang, Henan, primary, Gicobi, Joanina K., primary, Hirdler, Jacob B., primary, Liu, Xin, primary, Ham, Hyoungjun, primary, Peterson Martinez, Kodi E., primary, Lucien, Fabrice, primary, Lavoie, Roxane R., primary, Li, Hu, primary, Correia, Cristina, primary, Monie, Dileep D., primary, An, Zesheng, primary, Harrington, Susan M., primary, Wu, Xiaosheng, primary, Guo, Ruifeng, primary, Dronca, Roxana S., primary, Mansfield, Aaron S., primary, Yan, Yiyi, primary, Markovic, Svetomir N., primary, Park, Sean S., primary, Sun, Jie, primary, Qin, Hong, primary, Liu, Minetta C., primary, Vasmatzis, George, primary, Billadeau, Daniel D., primary, and Dong, Haidong, primary

Published
2024
Full Text
View/download PDF

4. Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8 + T cells via ME1 up-regulation

Author

Gicobi, Joanina K., primary, Mao, Zhiming, additional, DeFranco, Grace, additional, Hirdler, Jacob B., additional, Li, Ying, additional, Vianzon, Vianca V., additional, Dellacecca, Emilia R., additional, Hsu, Michelle A., additional, Barham, Whitney, additional, Yan, Yiyi, additional, Mansfield, Aaron S., additional, Lin, Yi, additional, Wu, Xiaosheng, additional, Hitosugi, Taro, additional, Owen, Dawn, additional, Grams, Michael P., additional, Orme, Jacob J., additional, Lucien, Fabrice, additional, Zeng, Hu, additional, Park, Sean S., additional, and Dong, Haidong, additional

Published
2023
Full Text
View/download PDF

6. A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma

Author

An, Zesheng, primary, Hsu, Michelle A., additional, Gicobi, Joanina K., additional, Xu, Tianxiao, additional, Harrington, Susan M., additional, Zhang, Henan, additional, Pavelko, Kevin D., additional, Hirdler, Jacob B., additional, Lohse, Christine M., additional, Nabavizadeh, Reza, additional, Pessoa, Rodrigo R., additional, Sharma, Vidit, additional, Thompson, R. Houston, additional, Leibovich, Bradley C., additional, Dong, Haidong, additional, and Lucien, Fabrice, additional

Published
2023
Full Text
View/download PDF

7. Resilient CD8 +T cells maintain a high cytotoxic capacity by balancing ROS and energy needs via ME1 upregulation

Author

Gicobi, Joanina K, primary, Mao, Zhiming, additional, DeFranco, Grace, additional, Li, Ying, additional, Liu, Xin, additional, Hirdler, Jacob H., additional, Vianzon, Vianca, additional, Dellacecca, Emilia R., additional, Hsu, Michelle A., additional, Barham, Whitney, additional, Kim, Yohan, additional, Abraha, Feven, additional, Harmsen, William, additional, Yan, Yiyi, additional, Dronca, Roxana S., additional, Zhu, Mojun, additional, Markovic, Svetomir, additional, Mansfield, Aaron, additional, Lin, Yi, additional, Wu, Xiaosheng, additional, Owen, Dawn, additional, Grams, Michael P., additional, Orme, Jacob J., additional, Lucien, Fabrice, additional, Zeng, Hu, additional, Park, Sean S., additional, and Dong, Haidong, additional

Published
2023
Full Text
View/download PDF

9. Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8+ T cells via ME1 upregulation.

Author

Gicobi, Joanina K., Zhiming Mao, DeFranco, Grace, Hirdler, Jacob B., Ying Li, Vianzon, Vianca V., Dellacecca, Emilia R., Hsu, Michelle A., Barham, Whitney, Yiyi Yan, Mansfield, Aaron S., Yi Lin, Xiaosheng Wu, Taro Hitosugi, Owen, Dawn, Grams, Michael P., Orme, Jacob J., Lucien, Fabrice, Hu Zeng, and Park, Sean S.

Abstract

Patients with advanced cancers who either do not experience initial response to or progress while on immune checkpoint inhibitors (ICIs) receive salvage radiotherapy to reduce tumor burden and tumor-related symptoms. Occasionally, some patients experience substantial global tumor regression with a rebound of cytotoxic CD8+ T cells. We have termed the rebound of cytotoxic CD8+ T cells in response to salvage therapy as T cell resilience and examined the underlying mechanisms of resilience. Resilient T cells are enriched for CX3CR1+ CD8+ T cells with low mitochondrial membrane potential, accumulate less reactive oxygen species (ROS), and express more malic enzyme 1 (ME1). ME1 overexpression enhanced the cytotoxicity and expansion of effector CD8+ T cells partially via the type I interferon pathway. ME1 also increased mitochondrial respiration while maintaining the redox state balance. ME1 increased the cytotoxicity of peripheral lymphocytes from patients with advanced cancers. Thus, preserved resilient T cells in patients rebound after salvage therapy and ME1 enhances their resiliency. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

10. Data from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

Author

Wen, Ti, primary, Barham, Whitney, primary, Li, Ying, primary, Zhang, Henan, primary, Gicobi, Joanina K., primary, Hirdler, Jacob B., primary, Liu, Xin, primary, Ham, Hyoungjun, primary, Peterson Martinez, Kodi E., primary, Lucien, Fabrice, primary, Lavoie, Roxane R., primary, Li, Hu, primary, Correia, Cristina, primary, Monie, Dileep D., primary, An, Zesheng, primary, Harrington, Susan M., primary, Wu, Xiaosheng, primary, Guo, Ruifeng, primary, Dronca, Roxana S., primary, Mansfield, Aaron S., primary, Yan, Yiyi, primary, Markovic, Svetomir N., primary, Park, Sean S., primary, Sun, Jie, primary, Qin, Hong, primary, Liu, Minetta C., primary, Vasmatzis, George, primary, Billadeau, Daniel D., primary, and Dong, Haidong, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

Author

Wen, Ti, primary, Barham, Whitney, primary, Li, Ying, primary, Zhang, Henan, primary, Gicobi, Joanina K., primary, Hirdler, Jacob B., primary, Liu, Xin, primary, Ham, Hyoungjun, primary, Peterson Martinez, Kodi E., primary, Lucien, Fabrice, primary, Lavoie, Roxane R., primary, Li, Hu, primary, Correia, Cristina, primary, Monie, Dileep D., primary, An, Zesheng, primary, Harrington, Susan M., primary, Wu, Xiaosheng, primary, Guo, Ruifeng, primary, Dronca, Roxana S., primary, Mansfield, Aaron S., primary, Yan, Yiyi, primary, Markovic, Svetomir N., primary, Park, Sean S., primary, Sun, Jie, primary, Qin, Hong, primary, Liu, Minetta C., primary, Vasmatzis, George, primary, Billadeau, Daniel D., primary, and Dong, Haidong, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Data from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

Author

Wen, Ti, primary, Barham, Whitney, primary, Li, Ying, primary, Zhang, Henan, primary, Gicobi, Joanina K., primary, Hirdler, Jacob B., primary, Liu, Xin, primary, Ham, Hyoungjun, primary, Peterson Martinez, Kodi E., primary, Lucien, Fabrice, primary, Lavoie, Roxane R., primary, Li, Hu, primary, Correia, Cristina, primary, Monie, Dileep D., primary, An, Zesheng, primary, Harrington, Susan M., primary, Wu, Xiaosheng, primary, Guo, Ruifeng, primary, Dronca, Roxana S., primary, Mansfield, Aaron S., primary, Yan, Yiyi, primary, Markovic, Svetomir N., primary, Park, Sean S., primary, Sun, Jie, primary, Qin, Hong, primary, Liu, Minetta C., primary, Vasmatzis, George, primary, Billadeau, Daniel D., primary, and Dong, Haidong, primary

Published
2023
Full Text
View/download PDF

14. Table S3 from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

Author

Baumeister, Susanne H., primary, Murad, Joana, primary, Werner, Lillian, primary, Daley, Heather, primary, Trebeden-Negre, Helene, primary, Gicobi, Joanina K., primary, Schmucker, Adam, primary, Reder, Jake, primary, Sentman, Charles L., primary, Gilham, David E., primary, Lehmann, Frédéric F., primary, Galinsky, Ilene, primary, DiPietro, Heidi, primary, Cummings, Kristen, primary, Munshi, Nikhil C., primary, Stone, Richard M., primary, Neuberg, Donna S., primary, Soiffer, Robert, primary, Dranoff, Glenn, primary, Ritz, Jerome, primary, and Nikiforow, Sarah, primary

Published
2023
Full Text
View/download PDF

15. Data from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

Author

Baumeister, Susanne H., primary, Murad, Joana, primary, Werner, Lillian, primary, Daley, Heather, primary, Trebeden-Negre, Helene, primary, Gicobi, Joanina K., primary, Schmucker, Adam, primary, Reder, Jake, primary, Sentman, Charles L., primary, Gilham, David E., primary, Lehmann, Frédéric F., primary, Galinsky, Ilene, primary, DiPietro, Heidi, primary, Cummings, Kristen, primary, Munshi, Nikhil C., primary, Stone, Richard M., primary, Neuberg, Donna S., primary, Soiffer, Robert, primary, Dranoff, Glenn, primary, Ritz, Jerome, primary, and Nikiforow, Sarah, primary

Published
2023
Full Text
View/download PDF

16. Figure S1 from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

Author

Baumeister, Susanne H., primary, Murad, Joana, primary, Werner, Lillian, primary, Daley, Heather, primary, Trebeden-Negre, Helene, primary, Gicobi, Joanina K., primary, Schmucker, Adam, primary, Reder, Jake, primary, Sentman, Charles L., primary, Gilham, David E., primary, Lehmann, Frédéric F., primary, Galinsky, Ilene, primary, DiPietro, Heidi, primary, Cummings, Kristen, primary, Munshi, Nikhil C., primary, Stone, Richard M., primary, Neuberg, Donna S., primary, Soiffer, Robert, primary, Dranoff, Glenn, primary, Ritz, Jerome, primary, and Nikiforow, Sarah, primary

Published
2023
Full Text
View/download PDF

17. A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration–Approved PD-1 and PD-L1 Inhibitors

Author

Barham, Whitney, primary, Hsu, Michelle, additional, Liu, Xin, additional, Harrington, Susan M., additional, Hirdler, Jacob B., additional, Gicobi, Joanina K., additional, Zhu, Xingxing, additional, Zeng, Hu, additional, Pavelko, Kevin D., additional, Yan, Yiyi, additional, Mansfield, Aaron S., additional, and Dong, Haidong, additional

Published
2023
Full Text
View/download PDF

18. Resilient CD8+T cells maintain a high cytotoxic capacity by balancing ROS via ME1 upregulation

Author

Gicobi, Joanina K., primary, Mao, Zhiming, additional, DeFranco, Grace, additional, Li, Ying, additional, Liu, Xin, additional, Hirdler, Jacob B., additional, Vianzon, Vianca V., additional, Dellacecca, Emilia R., additional, Hsu, Michelle A., additional, Barham, Whitney, additional, Kim, Yohan, additional, Abraha, Feven, additional, Harmsen, William S., additional, Yan, Yiyi, additional, Dronca, Roxana S., additional, Zhu, Mojun, additional, Markovic, Svetomir N., additional, Mansfield, Aaron S., additional, Lin, Yi, additional, Wu, Xiaosheng, additional, Owen, Dawn, additional, Grams, Michael P., additional, Orme, Jacob J., additional, Lucien, Fabrice, additional, Zeng, Hu, additional, Park, Sean S., additional, and Dong, Haidong, additional

Published
2022
Full Text
View/download PDF

19. Discovery of a novel monoclonal PD-L1 antibody H1A that promotes T-cell mediated tumor killing activity in renal cell carcinoma

Author

An, Zesheng, primary, Hsu, Michelle A., additional, Gicobi, Joanina K., additional, Xu, Tianxiao, additional, Harrington, Susan M., additional, Zhang, Henan, additional, Pavelko, Kevin D., additional, Hirdler, Jacob B., additional, Lohse, Christine M., additional, Nabavizadeh, Reza, additional, Pessoa, Rodriguo R., additional, Sharma, Vidit, additional, Thompson, R. Houston, additional, Leibovich, Bradley C., additional, Dong, Haidong, additional, and Lucien, Fabrice, additional

Published
2022
Full Text
View/download PDF

21. A novel humanized PD-1/PD-L1 mouse model permits direct comparison of anti-tumor immunity generated by FDA-approved PD-1 and PD-L1 inhibitors

Author

Barham, Whitney, primary, Hsu, Michelle, additional, Liu, Xin, additional, Harrington, Susan M., additional, Hirdler, Jacob B., additional, Gicobi, Joanina K., additional, Zhu, XingXing, additional, Zeng, Hu, additional, Pavelko, Kevin D., additional, Yan, Yiyi, additional, Mansfield, Aaron S., additional, and Dong, Haidong, additional

Published
2022
Full Text
View/download PDF

22. NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

Author

Wen, Ti, primary, Barham, Whitney, additional, Li, Ying, additional, Zhang, Henan, additional, Gicobi, Joanina K., additional, Hirdler, Jacob B., additional, Liu, Xin, additional, Ham, Hyoungjun, additional, Peterson Martinez, Kodi E., additional, Lucien, Fabrice, additional, Lavoie, Roxane R., additional, Li, Hu, additional, Correia, Cristina, additional, Monie, Dileep D., additional, An, Zesheng, additional, Harrington, Susan M., additional, Wu, Xiaosheng, additional, Guo, Ruifeng, additional, Dronca, Roxana S., additional, Mansfield, Aaron S., additional, Yan, Yiyi, additional, Markovic, Svetomir N., additional, Park, Sean S., additional, Sun, Jie, additional, Qin, Hong, additional, Liu, Minetta C., additional, Vasmatzis, George, additional, Billadeau, Daniel D., additional, and Dong, Haidong, additional

Published
2021
Full Text
View/download PDF

27. Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

Author

Baumeister, Susanne H., primary, Murad, Joana, additional, Werner, Lillian, additional, Daley, Heather, additional, Trebeden-Negre, Helene, additional, Gicobi, Joanina K., additional, Schmucker, Adam, additional, Reder, Jake, additional, Sentman, Charles L., additional, Gilham, David E., additional, Lehmann, Frédéric F., additional, Galinsky, Ilene, additional, DiPietro, Heidi, additional, Cummings, Kristen, additional, Munshi, Nikhil C., additional, Stone, Richard M., additional, Neuberg, Donna S., additional, Soiffer, Robert, additional, Dranoff, Glenn, additional, Ritz, Jerome, additional, and Nikiforow, Sarah, additional

Published
2019
Full Text
View/download PDF

28. NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy.

Author

Wen T, Barham W, Li Y, Zhang H, Gicobi JK, Hirdler JB, Liu X, Ham H, Peterson Martinez KE, Lucien F, Lavoie RR, Li H, Correia C, Monie DD, An Z, Harrington SM, Wu X, Guo R, Dronca RS, Mansfield AS, Yan Y, Markovic SN, Park SS, Sun J, Qin H, Liu MC, Vasmatzis G, Billadeau DD, and Dong H

Subjects
Animals, Humans, Mice, T-Lymphocytes, Cytotoxic, CD8-Positive T-Lymphocytes immunology, Immunotherapy, Membrane Proteins metabolism, Neoplasms immunology, Neoplasms therapy, RNA, Messenger therapeutic use
Abstract

Cytotoxic CD8 + T cells (CTL) are a crucial component of the immune system notable for their ability to eliminate rapidly proliferating malignant cells. However, the T-cell intrinsic factors required for human CTLs to accomplish highly efficient antitumor cytotoxicity are not well defined. By evaluating human CD8 + T cells from responders versus nonresponders to treatment with immune checkpoint inhibitors, we sought to identify key factors associated with effective CTL function. Single-cell RNA-sequencing analysis of peripheral CD8 + T cells from patients treated with anti-PD-1 therapy showed that cells from nonresponders exhibited decreased expression of the cytolytic granule-associated molecule natural killer cell granule protein-7 ( NKG7 ). Functional assays revealed that reduced NKG7 expression altered cytolytic granule number, trafficking, and calcium release, resulting in decreased CD8 + T-cell-mediated killing of tumor cells. Transfection of T cells with NKG7 mRNA was sufficient to improve the tumor-cell killing ability of human T cells isolated from nonresponders and increase their response to anti-PD-1 or anti-PD-L1 therapy in vitro . NKG7 mRNA therapy also improved the antitumor activity of murine tumor antigen-specific CD8 + T cells in an in vivo model of adoptive cell therapy. Finally, we showed that the transcription factor ETS1 played a role in regulating NKG7 expression. Together, our results identify NKG7 as a necessary component for the cytotoxic function of CD8 + T cells and establish NKG7 as a T-cell-intrinsic therapeutic target for enhancing cancer immunotherapy. See related article by Li et al., p. 154., (©2021 The Authors; Published by the American Association for Cancer Research.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results